DDInter1804 DDInter1747
Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine.
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Ticlopidine {u} may lead to a major life threatening interaction when taken with {v} Clopidogrel
Ticlopidine {u} (Compound) binds {v} (Gene) MPO
Ticlopidine {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Platelet Aggregation
Ticlopidine {u} (Compound) downregulates {v} (Gene) RPS4Y1
Ticlopidine {u} (Compound) causes {v} (Side Effect) Flatulence
Ticlopidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Turmeric
Ticlopidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alteplase
Ticlopidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Stiripentol
Ticlopidine {u} may lead to a major life threatening interaction when taken with {v} Drotrecogin alfa
Ticlopidine may lead to a major life threatening interaction when taken with Clopidogrel
Ticlopidine (Compound) binds MPO (Gene)
Ticlopidine (Compound) is included by Decreased Platelet Aggregation (Pharmacologic Class)
Ticlopidine (Compound) downregulates RPS4Y1 (Gene)
Ticlopidine (Compound) causes Flatulence (Side Effect)
Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Turmeric
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Alteplase
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Ticlopidine may lead to a major life threatening interaction when taken with Drotrecogin alfa